Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)

Pfiz­er's Al­bert Bourla spells out 'tran­si­tion year' for Covid prod­ucts, with sales ex­pect­ed to reach a low point

On the heels of a record sales year, Pfiz­er is brac­ing for im­pact as it ex­pects Covid-19 rev­enue to bot­tom out in 2023.

That’s due to low­er com­pli­ance with vac­cine rec­om­men­da­tions, few­er pri­ma­ry vac­cines be­ing ad­min­is­tered, and a “sig­nif­i­cant” gov­ern­ment sup­ply that’s ex­pect­ed to last through­out ear­ly this year, ex­ecs said Tues­day on the com­pa­ny’s Q4 earn­ings call.

CEO Al­bert Bourla an­tic­i­pates $13.5 bil­lion in Comir­naty sales this year, down 64% from 2022, and just $8 bil­lion in Paxlovid rev­enue, down 58% from 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.